Orgenesis Inc. Stock News
$1.20
0.42%
day before yesterday
Nasdaq,
Nov 01, 08:18 pm CET
Orgenesis Inc. Stock News
Neutral
GlobeNewsWire
●
2 months ago
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study
Neutral
GlobeNewsWire
●
3 months ago
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed j...
Neutral
GlobeNewsWire
●
6 months ago
Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
